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The detection of elevated cardiac enzyme levels and the
occurrence of electrocardiographic (ECG) abnormalities after
revascularization procedures have been the subject of recent
controversy. This report represents an effort to achieve a consen-
sus among a group of researchers with data on this subject.
Creatine kinase (CK) or CK-MB isoenzyme (CK-MB) elevations
occur in 5% to 30% of patients after a percutaneous intervention
and commonly during coronary artery bypass graft surgery
(CABG). Although Q wave formation is rare, other ECG changes
are common. The rate of detection is highly dependent on the
intensity of enzyme and ECG measurement. Because most events
occur without the development of a Q wave, the ECG will not
definitively diagnose them; even the ECG criteria for Q wave
formation signifying an important clinical event have been vari-
able. At least 10 studies evaluating >10,000 patients undergoing
percutaneous intervention have demonstrated that elevation of
CK or CK-MB is associated not only with a higher mortality, but
also with a higher risk of subsequent cardiac events and higher
cost. Efforts to identify a specific cutoff value below which the
prognosis is not impaired have not been successful. Rather, the
risk of adverse outcomes increases with any elevation of CK or
CK-MB and increases further in proportion to the level of
intervention. This information complements similar previous data
on CABG. Obtaining preprocedural and postprocedural ECGs
and measurement of serial cardiac enzymes after revasculariza-
tion are recommended. Patients with enzyme levels elevated more
than threefold above the upper limit of normal or with ECG
changes diagnostic for Q wave myocardial infarction (MI) should
be treated as patients with an MI. Patients with more modest
elevations should be observed carefully. Clinical trials should
ensure systematic evaluation for myocardial necrosis, with atten-
tion paid to multivariable analysis of risk factors for poor
long-term outcome, to determine the extent to which enzyme
elevation is an independent risk factor after considering clinical
history, coronary anatomy, left ventricular function and clinical
evidence of ischemia. In addition, tracking of enzyme levels in
clinical trials is needed to determine whether interventions that
reduce periprocedural enzyme elevation also improve mortality.
(J Am Coll Cardiol 1998;31:241–51)
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When cardiac enzymes are measured after coronary revascu-
larization procedures, 5% to 30% of patients have elevated
levels of creatine kinase (CK) or its MB subfraction (CK-MB),
and similar proportions of patients develop electrocardio-
graphic (ECG) changes. Because these findings raise funda-
mental issues in clinical practice and clinical research, a group
of clinical investigators who had produced relevant data re-
cently convened to review the available evidence and to
attempt to reach a consensus concerning recommendations for
clinical practice and clinical investigation.
This review appears in the midst of a sweeping change in
society’s view of medical illness and health care delivery, in that
evidence of a good clinical outcome is the basis for acceptance
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of therapeutic approaches. In this context ischemic heart
disease can be considered a chronic illness characterized by
periods of quiescence punctuated by acute events, including
death, myocardial infarction (MI) and symptoms of angina or
congestive heart failure. Therapies designed to improve pa-
tient outcome in ischemic heart disease generally are consid-
ered worthwhile if they improve all three outcomes, particu-
larly if the incremental cost is within the accepted societal
range (1). Revascularization, by either coronary artery bypass
graft surgery (CABG) or percutaneous revascularization pro-
cedures, is increasingly being used in the treatment of symp-
tomatic ischemic heart disease. The relevance of enzyme rises,
representing possible myocardial necrosis (myonecrosis) dur-
ing the procedures, and the extent to which these enzyme rises
constitute an undesirable clinical outcome, will be important
considerations in the debate about which procedures should be
used in which patients.
Because the primary goals of therapy for patients with
coronary artery disease are to reduce anginal symptoms and to
prevent major ischemic complications, a number of investiga-
tors have begun to study ECG changes and elevations in
enzyme levels in the circulation after percutaneous procedures,
which may reflect myocardial cell damage during the proce-
dure. This issue has been a topic of interest for several decades
with regard to CABG (2,3), but uncertainty regarding the
usefulness of CK-MB as a measure of perioperative injury
arose when increases in enzyme levels were noted in the
absence of clinically apparent cardiac damage (4), and this
issue has yet to be clarified. The recent introduction of
pharmacologic agents designed to reduce the extent or conse-
quences of myocardial injury during surgical treatment and the
advent of less invasive surgical techniques have stimulated
renewed interest. Scrutiny of enzyme elevations after percuta-
neous procedures has intensified as enzyme elevations have
been observed more frequently with the use of new technolo-
gies (5,6).
The impetus for resolving the diagnostic criteria for myo-
cardial necrosis comes from two sources: the clinical issue of
whether a patient should be treated differently after such an
episode and the uncertain place of isolated enzyme events or
ECG changes in assessing the value of a procedure. In clinical
practice, new ECG changes or elevated cardiac enzymes may
affect the need for hospital admission, the length of hospital
stay, the intensity of follow-up or postdischarge pharmacologic
therapy. For clinical trials evaluating new and current thera-
pies, differences in these measures may provide a means of
distinguishing which therapy is associated with better out-
comes. Alternatively, if small “leaks” of cardiac enzymes or
periprocedural ECG abnormalities have no significance in
terms of patient outcome, counting these events as MIs would
be misleading in a therapeutic evaluation.
Diagnostic Methods
Despite nearly universal agreement that episodes of myo-
cardial necrosis are to be avoided whenever possible, the
continuing evolution of diagnostic technology makes the pre-
cise clinical definition of myocardial infarction a moving target.
The classic definition is the standard set by the World Health
Organization (WHO) almost 20 years ago (Table 1) (7). A
decade ago a clinical definition of acute MI evolved which is
based on an evaluation of both total CK and CK-MB and the
ECG. With this definition, which was based on the evaluation
of CK and CK-MB by an immunoassay, a patient who had at
least a doubling of total CK with .5% of the total representing
the CK-MB would be classified as having an MI. More
recently, CK-MB assays are predominantly mass assays,
whereas total CK assays remain immunoassays. In these cir-
cumstances, a 5% proportion of two different assays may be
misleading as they measure different components (mass and
activity) (8). Therefore, the diagnosis of acute MI now mostly
rests on an abnormal (above the upper normal range, most
commonly 5 to 10 mg/ml, depending on assay characteristics)
CK-MB mass level in addition to ECG findings. However,
many patients with symptomatic episodes of acute myocardial
ischemia have enzymatic evidence of myocardial necrosis
associated with an increased risk of poor clinical outcomes but
do not meet WHO criteria (9). In one series, 10% of patients
with an elevated CK-MB measurement had a normal total CK
(10), whereas a second series demonstrated a 22% 1-year
mortality rate in patients with minimally elevated CK-MB,
mostly due to comorbid medical conditions (11). The release
of some CK-MB may be expected as a routine sequela of
CABG, but some investigators have shown a qualitative rela-
tion between release of CK-MB and poor outcome. Similarly,
Abbreviations and Acronyms
CABG 5 coronary artery bypass graft surgery
CK 5 creatine kinase
CK-MB 5 creatine kinase, MB isoenzyme
ECG 5 electrocardiogram, electrocardiographic
MI 5 myocardial infarction
PTCA 5 percutaneous transluminal coronary angioplasty
Tn 5 troponin
WHO 5 World Health Organization
Table 1. World Health Organization Definition of Acute
Myocardial Infarction










AMI 5 acute myocardial infarction; ECG 5 electrocardiographic.
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studies have demonstrated that elevations of CK-MB above
the upper limit of normal occur commonly after percutaneous
transluminal coronary angioplasty (PTCA), but the threshold
for defining an MI in this setting remains an enigma.
Not only are the appropriate enzyme criteria uncertain, but
the criteria for interpretation of the ECG in the diagnosis of
MI are also not as clear as commonly believed. Development
of new Q waves is uncommon after a percutaneous interven-
tion, with reported incidences of Q wave MI of 1% to 3%, but
other ECG changes are common, and the meaning of QRS
changes after surgical treatment has been the source of
considerable debate (12).
Methodology of Determining Q Wave MI
A variety of Q wave criteria have been proposed for
determining whether an ECG reflects new myocardial necro-
sis, including 1) a new 2-grade Q wave worsening of the
Minnesota code; 2) a new 1-grade worsening of the Minnesota
code with major ST-T wave worsening; 3) new 30-ms Q waves
in two contiguous leads; 4) new 30-ms Q waves in two
contiguous leads at least 1 mm deep; 5) new 40-ms Q waves;
and 6) pathologic Q waves (13–20). Incident rates of Q wave
events can vary considerably depending on the definition used.
Of the various Q wave criteria proposed, the Minnesota code
is one of the few validated coding systems used extensively in
epidemiologic studies and large-scale clinical trials (13–15).
The Minnesota Q wave codes categorize changes in the
anterior, inferior and lateral lead groups based on the width
and depth of the Q wave and Q/R wave ratio. A distinction is
made between Q wave and QS complexes. In autopsy series,
the specificity of major Q wave codes for myocardial necrosis
exceeds 90% (21,22). In patients with autopsy evidence of MI,
30% to 40% of patients will have major Minnesota code Q
waves and 60% will have major or minor Minnesota code Q
waves. The sensitivity of Minnesota code Q wave criteria is
greater in patients with recent evidence of MI.
The recently revised WHO criteria use the Minnesota code
to define Q wave evidence of MI (13). The new development
of a 2-grade Q wave worsening or a 1-grade Q wave worsening
with major ST segment elevation or depression is defined as a
definite MI on the ECG. When the Minnesota code is used for
serial comparison, the NOVACODE or other serial compari-
son algorithm should be used to adjust for biologic noise
resulting in minor threshold changes that can produce false
positive diagnoses (14).
The evolution of myocardial ischemia or necrosis can result
in significant ECG changes over time. In the Program Of
Surgical Control of Hyperlipidemia (POSCH), 34% of subjects
with codeable Minnesota code Q wave items lost a codeable
Q-QS pattern after an average 2.2 years (23). Ascertainment of
major ST-T wave abnormalities during acute ischemia will be
dependent in part on the timing of ECG acquisition. Q waves
may develop instantaneously or over several hours or days.
Large-scale clinical trials of patients with spontaneous myocar-
dial ischemia, persistent for .30 min and associated with ST
segment elevation .1 mm, have found abnormal cardiac
enzyme panels in .90% of patients, and new Q waves develop
in 70% to 80% of patients without a previous history of MI.
Evaluation of ECGs for new Q waves in a critical care setting
may be further confounded by inconsistent patient position
and lead placement, especially in an unstable patient. ECG
scoring systems to determine the extent of myocardial necrosis
may provide additional incremental information on prognosis,
but have not been widely applied to detection of MI (24).
The Selvester QRS score is another method that has been
validated for estimating the size of anterior, inferior and
posterolateral infarcts (25–28). A set of three screening criteria
for the Selvester system has been shown to achieve high
specificity in control populations (95%) and moderate sensi-
tivities for identifying anterior (67%), inferior (90%) and
posterolateral (45%) infarction (29,30). The term “new signif-
icant Q waves in at least two anatomically contiguous leads” is
commonly used in definitions of new MI. Using the Selvester
system, this definition for the various leads would be Q waves
$30 ms for leads I and aVL (lateral); $30 ms for leads II and
aVF (inferior); $30 ms for leads V5 and V6 (apical); any Q
wave length for leads V1 to V3; and $20 ms for lead V4
(anterior) (31).
Despite the acceptance of the clinical importance of Q wave
MI, the relation between Q wave formation and subsequent
outcome after PTCA has not been intensively investigated.
Only the National Institutes of Health PTCA registry (32) has
documented subsequent increased mortality. After CABG,
QRS changes are common, and new Q waves have been
associated with subsequent mortality (16), but conduction
disturbances are common, causing difficulty in interpretation.
The recent finding in both the Bypass Angioplasty Revascular-
ization Investigation (BARI) (33) and Emory Angioplasty
Surgery Trial (EAST) (34) of a higher rate of Q wave MI after
CABG than after PTCA has raised the question of whether
these Q waves represent the same entity as a Q wave in a
medically treated patient. Preliminary reports showed no dif-
ferences in systolic function despite the higher rate of Q waves
in surgically treated patients.
General Meaning of Elevated
Cardiac Enzymes
The interpretation of elevated CK and CK-MB as markers
of myocardial necrosis is based on the systematic study defining
the pathogenic mechanisms of CK release from the myocar-
dium. In human myocardium CK is present in high activity as
a dimer composed of two subunits (35–37). Approximately
15% of total CK activity in human myocardium is composed of
the MB isoenzyme, 75% of the MM isoenzyme and the
remaining 10% of a separate isoenzyme—the mitochondrial
isoenzyme (CK-MT), present as an octamer (35,36,38). Al-
though all CK-MT activity is bound to mitochondrial mem-
branes, ;50% of the CK-MM and CK-MB activity is bound to
myofibrils (39). Creatine kinase catalyzes the reaction that
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transfers high energy phosphate groups between creatine
phosphate and adenosine triphosphate. The presence of the
intact enzyme is critical to normal myocardial function. Bio-
chemical inhibition of CK interferes with the full range of
cardiac performance in isolated hearts (40). Studies in trans-
genic mice (41,42) show that the B-knockout is lethal, whereas
the M-knockout, MT-knockout and double knockout survive
with remarkable histologic changes. The M-knockout has an
increase in mitochondrial mass, and the myocardium in the
double knockout appears almost identical histologically to
insect flight muscle with dense packages of mitochondria
between thin bundles of myofibrils (41,42). The critical role of
CK is further attested by an apparent absence of phenotypic
polymorphism (43), although post-translational modification
of CK-MB in plasma produces CK-MB “isoforms” (44).
Several experimental studies have identified the pathologic
conditions necessary for CK release from the myocardium. A
close correlation between CK release and disruption in cellular
ultrastructure has been documented in anoxic isolated heart
preparations from several species (45). In a canine preparation
of ischemia and infarction, elevation of serum CK is seen in the
presence of histologic evidence of micronecrosis or frank
infarction (46). Although only one-seventh of total tissue CK is
recoverable in serum (47,48), the amount of CK released
correlates with the size of experimental infarcts (49,50). Cre-
atine kinase is released in response to anoxic injury in relation
to the ability to maintain or recover a cellular potassium
gradient—an accurate index of irreversible cell injury (51).
Several other metabolic derangements, such as irreversible loss
of mitochondrial respiratory function and unrestorable dis-
sociation of the CK-MT from mitochondrial membranes,
precede measurable decreases in myocardial CK in the post-
ischemic isolated rabbit heart (52). Moderate irreversible
derangements in mitochondrial respiratory function and global
left ventricular function precede decreases in total myocardial
CK activity in the isolated ferret heart (53).
The pathogenic mechanisms of myocardial enzyme release
include depletion of high energy phosphate compounds
(46,47,49,50,54), H1 and phosphate accumulation leading to
solubilization of bound CK (45,52) and leakage of enzyme
through disrupted sarcolemma (48,51). Although the specific-
ity of other markers such as troponins I and T for myocardial
necrosis is not firmly established (55,56), the majority of
studies indicate that CK-MB is not released in the absence of
myocardial necrosis (45–53), although some disagreement
exists.
The detection of CK-MB in serum, however, is not entirely
specific for myocardial necrosis. Skeletal muscle has a fourfold
higher CK content than myocardium (35,36,57), contains mea-
surable CK-MB activity (2%) (35,36,57) and has a lower
fraction of bound CK (10%) (39). Because irreversible injury is
not required for CK release from the large mass of skeletal
muscle, ;2% to 4% of circulating background CK activity in
normal serum is composed of CK-MB activity that is predom-
inantly of skeletal muscle origin (48,58,59). The clinical diag-
nosis of myocardial necrosis is thus based on serial sampling
showing a characteristic pattern of rise in CK-MB activity after
an episode of possible myocardial injury (14). Within 4 to 6 h
after the onset of acute MI, both total CK and CK-MB
activities rise above the threshold level. The delay in the
appearance of CK activity in serum is attributed to the time
required for ischemic injury to result in irreversible myocardial
high energy phosphate depletion, solubilization of bound
intracellular CK, transfer of CK to myocardial lymph through
disrupted sarcolemma and diffusion into the central circulation
(48). Creatine kinase activity peaks within 10 to 20 h after the
onset of infarction and returns to baseline within 2 to 3 days
(58,59). Therefore, the characteristic rise and fall of CK or
CK-MB activity after coronary angioplasty is highly likely to be
related to the presence of myocardial necrosis.
The timing of the CK rise, peak and fall, as well as the
magnitude of peak CK changes, is dependent on the timing of
the coronary occlusion and reperfusion of the culprit artery.
Because most ischemic episodes in patients with acute isch-
emic syndromes are asymptomatic, spontaneous ischemic epi-
sodes before or during revascularization procedures cannot be
excluded. Some of these spontaneous episodes are likely to be
sufficiently severe to be associated with CK release. However,
because the onset of the asymptomatic episode was unrecog-
nized and the revascularization procedure altered the kinetics
of CK release, the precise timing relation between the revas-
cularization procedure and the peak CK may be very difficult
to interpret. Reperfusion shortens the time to peak CK,
increases the absolute peak and makes the fall more rapid.
Because most revascularization procedures improve flow in the
culprit artery, the characteristic CK release pattern and sub-
sequent washout into systemic blood seen in de novo MI would
be expected to be altered after a percutaneous revasculariza-
tion procedure whenever there is CK release.
It is unclear whether thresholds can be determined for
enzymatic markers such as CK and CK-MB and whether these
thresholds are specific enough to differentiate between routine
myocardial damage due to the procedure and myocardial
injury severe enough to adversely affect long-term outcome.
There are also limitations in the application of ECG criteria
for the identification of perioperative infarction: minor ECG
changes may be seen with pericardial inflammation, and
conduction disturbances frequently conceal significant myocar-
dial damage. Newer markers such as troponin T and I appear
to have higher specificity for myocardial necrosis and may be
more favorable for use in the perioperative period, but the
appropriate thresholds for prognostically significant injury
remain unclear.
Although newer markers of myocardial necrosis have been
shown to have considerable promise (60–62), CK-MB remains
the reference standard for diagnosis (63). Myocardial tissue
contains a variety of molecular species (or components), many
of which also exist in skeletal muscle. These nonspecific
macromolecules, such as myoglobin (64), CK isoenzymes (65)
and myosin light chains (66), have been found to be excellent
early markers of MI, as they frequently appear in serum within
1 to 2 h of the onset of symptoms. However, these tests lack
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cardiac specificity, which makes them useful as screening tests
but not as diagnostic tests for periprocedural MI.
The troponin complex is a group of three proteins (TnT,
TnI and TnC) that act together to regulate muscle contraction
through the tropomyosin complex. Although this complex
exists in both cardiac and skeletal muscle, the isoforms of TnI
and TnT have significantly different protein structures, allow-
ing sensitive assays to be developed for their cardiac-specific
forms (66). The proteins TnT and TnI have been shown to
have prognostic value beyond CK-MB in acute ischemic syn-
dromes (61,62), but both analytes have long circulating half-
lives (5 to 14 days), so that new episodes of necrosis cannot
easily be separated from earlier episodes. Both TnT and TnI
have a high level of sensitivity and specificity for the diagnosis
of acute MI (63,67). Several investigations have used TnT or
TnI to diagnose periprocedural infarction (56,68–70). In one
study, 60% of patients having angioplasty had elevated TnT
(.0.04 ng/ml), whereas elevated CK was observed in only 16%.
In all patients who had a balloon inflated for .5 min TnT was
elevated (56). The clinical significance of the TnT elevations
remains to be established because none of the patients studied
had any significant adverse events. Further studies are required
to evaluate the implications of the high rate of elevation of the
cardiac troponin markers to diagnose minor MI and its signif-
icance.
Surgical Revascularization
Although currently available data on surgical revasculariza-
tion are more limited than are data on percutaneous revascu-
larization, there is substantial empiric evidence to support the
common sense concept that patients with perioperative isch-
emic injury fare less well than those without damage. Periop-
erative MIs as determined by ECG criteria are associated with
worse long-term outcome (71). Small transient increases in
CK-MB, representing ,1.5% of the total CK, may occur
routinely, but larger CK-MB elevations with and without ECG
changes have been associated with evidence of myocardial
damage by perfusion imaging and pathologic examination
(3,72,73). More recent data in patients with cardiac disease
undergoing noncardiac surgery also confirm that perioperative
ischemic events are predictive of subsequent complications
(74), but the threshold separating routine perioperative eleva-
tion from substantial damage of prognostic importance is not
clear.
The parallels between surgical and percutaneous revascu-
larization suggest a similar need for high quality data in the
perioperative period to clarify the relation between elevation
of biochemical markers and subsequent cardiac morbidity. In
the meantime, it appears that perioperative events involving
injury to a large amount of myocardium are associated with
increased risk and poorer outcome. Identification of new Q
waves in a postoperative ECG or elevation of CK-MB five
times or more above the normal limit, representing .3% total
CK, are considered quantitative evidence of important myo-
cardial injury in the perioperative period. A gradient of risk
similar to that suggested by data for percutaneous interven-
tions may exist for surgical patients, but at this time the
prognostic implications of lesser elevations of CK-MB or
increases in other biochemical markers are uncertain.
Percutaneous Revascularization
Multiple institutions have now reported follow-up studies of
percutaneous revascularization, and the evidence strongly sup-
ports a relation between the appearance of CK-MB in the
circulation and poorer clinical outcomes during subsequent
clinical evaluations. Elevated enzymes are associated with a
higher risk of death, subsequent MI and a need for repeat
revascularization procedures. The level of risk seems to in-
crease as a continuous function, with no obvious threshold
effect or “cutoff” value. Subsequent risk is clearly elevated in
patients with abrupt vessel closure, side branch occlusion,
thrombus formation or major dissection, but even when these
complications are not reported by the clinician, the risk of
subsequent poor outcome remains increased when an elevated
CK-MB is measured after the procedure. In patients with low
level elevations of CK-MB, the in-hospital risk appears to be
low, but the intermediate- and long-term risk appears to be
elevated. Attempts to adjust for other prognostic factors have
found enzyme rises to be independently predictive of adverse
outcomes.
Klein et al. (5) initially reported that 15% of a consecutive
series of 249 patients treated with angioplasty in 1989 and 1990
had elevations of total CK or CK-MB. Acute symptomatic
events were evident in almost half the patients whose CK-MB
became elevated in the presence of normal CK. Based on these
findings, the investigators made a plea for more follow-up
studies with larger numbers of patients.
In the most detailed long-term follow-up study to date,
Abdelmeguid et al. (75) demonstrated a direct relation be-
tween elevation of CK and CK-MB and risk of acute or chronic
complications in 4,863 consecutive patients who had a success-
ful percutaneous procedure. After excluding patients with an
unsuccessful procedure, 88 patients with transient abrupt
closure in the laboratory followed by successful opening of the
vessel were compared with 4,775 patients without abrupt
closure. The mortality rate of patients with abrupt closure and
no rise in CK-MB was no different from that of patients with
successful procedures without abrupt closure. However, when
CK-MB was elevated, the mortality rate was significantly
higher. In a multivariable regression analysis, an increase in
CK-MB was the most important independent predictor of
adverse outcomes in follow-up. This relation remained signif-
icant after controlling for a variety of clinical, morphologic and
procedural factors.
In a follow-up study, these investigators evaluated the
baseline characteristics, cardiac enzymes and clinical outcomes
of 4,797 patients with successful percutaneous procedures (76).
Patients with elevated CK levels more often had thrombus-
associated lesion characteristics, saphenous vein graft lesions
and use of directional atherectomy. Characteristics associated
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with CK elevation included a coronary embolism during the
procedure, a history of recent MI, minor procedural compli-
cations (transient abrupt closure), hypotension, vein graft
procedures, complex lesions, large dissections and severe
preprocedural stenoses. A continuous relation was observed
between the level of CK-MB and the risk of death over an
average follow-up period of .3 years (Fig. 1).
In a more recent study, Abdelmeguid et al. (77) evaluated
4,484 patients at the Cleveland Clinic whose maximal CK was
less than two times the upper limit of normal. Recent MI
(,36 h), “salvage” atherectomy for failed PTCA and chronic
total occlusion procedures were excluded. Within this re-
stricted group, a continuous relation was also found between
the level of CK-MB elevation and the risk of death in
follow-up, again with no evident threshold (77). Kugelmass et
al. (6) evaluated 565 patients treated with directional atherec-
tomy and stenting at a single institution. Elevation of CK-MB
with a peak value ,50 IU/liter occurred in 11.5% of patients
and was associated with no significant increase in adverse
2-year outcomes. In contrast, the 2.3% of patients with a
CK-MB level .50 IU/liter had a significant increase in poor
outcomes. Enzyme elevation was associated with a greater
extent of coronary disease and more adverse lesion morpho-
logic characteristics.
Harrington et al. (78) reported on findings in 1,012 patients
enrolled in the randomized Coronary Angioplasty Versus
Figure 1. Plots showing freedom
from cardiac (top) and noncardiac
(bottom) death according to postpro-
cedural cardiac enzyme level. Re-
printed, with permission, from Ab-
delmeguid et al. (77).
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Excisional Atherectomy Trial (CAVEAT) comparing exci-
sional atherectomy with angioplasty. Atherectomy was associ-
ated with a greater incidence of enzyme-positive events, and
threefold or greater increases in CK-MB were associated with
higher rates of repeat revascularization, longer hospital stay
and greater cost. Surprisingly, these enzyme rises were also
associated with a higher rate of 1-year mortality (79). Even in
the absence of clinically recognized abrupt closure, enzyme
elevation was associated with adverse clinical outcomes in
CAVEAT.
Topol et al. (80) published the long-term outcomes of
patients entered into the Evaluation of 7E3 for the Prevention
of Ischemic Complications (EPIC) trial as a function of
CK-MB elevation. A stepwise increase in the 3-year rise of
death was observed, ranging from a risk ratio of 1.47, with an
increase in the CK-MB ratio between one and two times the
upper limit of normal, to a risk ratio of 2.40 for patients with
an elevation more than 10 times the upper limit of normal.
Recently, a number of institutional and group experiences with
cardiac enzymes have been reported in abstract form (Table 2).
In the most extensive series reported to date, Redwood et al.
(81) compared 499 patients treated with direct coronary
atherectomy who had CK-MB elevations one to four times the
upper limit of normal with 1,148 patients treated with direc-
tional coronary atherectomy without an enzyme rise and with
250 patients with a greater enzyme rise. The low level enzyme
elevations were associated with a threefold increase in major
in-hospital complications and in late mortality. Data from both
the Integrelin to Manage Platelet Aggregation and Prevent
Coronary Thrombosis (IMPACT II) and Global Use of Strat-
egies to Open Occluded Coronary Arteries (GUSTO II) trials
have supported these findings (82,83). These studies also
documented a substantial increase in medical costs for patients
with elevated cardiac enzymes.
Most recently, a detailed single-center analysis from North-
western evaluated 253 consecutive patients with elevated CK
and 120 control patients in a case-control study (84). Elevation
of CK was a significant independent predictor of cardiac
mortality (Fig. 2) and mortality or subsequent MI, even after
considering coronary anatomy and left ventricular function,
and this relation did not have an obvious threshold. Based on
these findings the investigators and editorial reviewers (85)
recommend routine assessment of CK and CK-MB.
Several recent randomized studies have failed to find a
relation between low levels of CK-MB release and higher late
mortality (86,87). These trials tended to enroll patients with
good left ventricular function and a modest extent of disease.
Mechanisms
At least two possible processes require discussion in terms
of mechanisms. The first is the mechanism responsible for CK
Table 2. Studies of Enzyme Elevation
Study (ref no.) Year Procedure Threshold Value No. of Pts Above Threshold
Level of Increased
Risk
Oh et al. (91) 1985 Elective PTCA, successful CK-MB .2% of total CK 128 20% None detected
Klein et al. (5) 1991 Elective PTCA, successful CK-MB $5% of total CK 249 15% None detected
Kugelmass et al. (6) 1994 DCA or stenting, successful CK-MB 10–50 IU/liter
(.1–53 ULN)




Harrington et al. (78) 1995 DCA or PTCA, both
successful and
unsuccessful




Abdelmeguid et al. (75) 1995 DCA or PTCA, successful,
with and without
transient AC
Total CK . ULN 4,863 Without AC, 12%;
with AC, 50%
1Death
Abdelmeguid et al. (76) 1996 DCA or PTCA, successful Group 2, 2–53 ULN 4,664 Group 2, 123% 1Death
Group 3, .53 ULN Group 3, 61% 1Death






Redwood et al. (98) 1996 DCA, Rotablator, ELCA CK-MB 1–43 ULN 1,897 — 1Death
CK-MB .43 ULN — 1Death
Kong et al. (99) 1996 PTCA CK .125 IU/liter;
CK-MB .4%
2,812 9% 1Death, MI
Tardiff et al. (82) 1996 PTCA CK-MB 1–33 ULN 2,432 14% 1Death
CK-MB 3–103 ULN 8% 1Death
AC 5 abrupt closure; CK 5 creatine kinase; CK-MB 5 creatine kinase, MB fraction; DCA 5 directional coronary atherectomy; ELCA 5 excimer laser coronary
angioplasty; MI 5 myocardial infarction; PTCA 5 percutaneous transluminal coronary angioplasty; Pts 5 patients; ref 5 reference; ULN 5 upper limit of normal;
1 5 increased.
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release and the second is the mechanism responsible for
adverse clinical outcomes. The mechanism(s) responsible for
CK release are either related to myocellular necrosis (e.g.,
occlusion due to embolization, side branch occlusion, with
subsequent reperfusion and washout) or not related to myo-
cellular necrosis. In the latter case, possible mechanisms
include profound ischemic injury but retention of cell viability,
enzyme induction or perhaps some other, as yet undescribed,
process. The mechanism(s) responsible for the adverse out-
come event could be as simple as those associated with other
types of myocellular necrosis (e.g., poor left ventricular func-
tion, heightened adrenergic state contributing to ischemia or
arrhythmogenesis, arrhythmogenesis itself related to refractory
period dispersion). Alternatively, it could be that the charac-
teristics of the vessel wall (e.g., endothelial dysfunction, inflam-
mation) or plaque (e.g., soft core, thin cap, high stress) that
lead to micronecrosis initially make the vessel or plaque
relatively more vulnerable to additional rupture or disruption
over the follow-up period and result in an adverse outcome
event.
Several studies have attempted to explore the basis for
leakage of cardiac enzymes during an angioplasty procedure.
In a study of 357 balloon inflations in 38 patients, ECG
evidence of myocardial ischemia was noted after an average of
20 s of balloon inflation, whereas elevations of CK were not
observed in patients with an ischemia duration ,5 min (88).
These findings have been corroborated in 110 patients in
whom no significant CK-MB elevation was observed during a
15-min balloon inflation with no ECG evidence of ischemia
(89). Several investigators have reported that percutaneous
interventions without clinically recognized complications are
not associated with a significant leak of myocardial enzymes
(68,89–91), while others have found minor elevations in
CK-MB in a minority of patients in whom no clear evidence for
ischemia could be documented (5,92). The most common
cause for elevated enzymes from available studies after angio-
plasty is minor branch occlusion during the procedure, which
occurs in approximately one-third of all patients with elevated
enzymes (5,70,91), whereas angiographic evidence of thrombus
in the vessel is associated with CK-MB elevations in 13% to
40% of patients. Other documented causes have included
intimal dissection, coronary spasm and distal embolization (5).
Distal embolization has been noted to be particularly common
in patients undergoing a percutaneous intervention in saphe-
nous vein grafts (93). In a series of 155 procedures, indepen-
dent predictors of distal embolization with subsequent enzyme
release included diffusely diseased vein graft (p 5 0.002),
presence of thrombus (p 5 0.006), ulcerated lesion surface
(p 5 0.007), large plaque volume (p 5 0.02) and marked
eccentricity (p 5 0.03) (93). Thus, thrombosis either of a side
branch or by distal embolization appears to be a major culprit
for enzyme leakage after angioplasty. This concept is further
supported by the findings of a high rate of periprocedural
infarctions and abrupt closure in patients with thrombus-laden
lesions (94,95).
Several recent trials of blockade of the platelet glycoprotein
IIb/IIIa receptor or potent antithrombotic compounds such as
hirudin or bivalirudin during percutaneous intervention have
demonstrated a reduction in the occurrence of myocardial
necrosis (20,69,96). These findings suggest that preventing
platelet aggregation or thrombosis may prevent a substantial
proportion of the events. In addition to platelet emboli,
embolization of plaque material, particularly with atherectomy
devices, could plug smaller vessels downstream. Although
side-branch occlusion almost certainly contributes to the over-
all picture, there is no evidence that it is a major issue in this
context.
The fact that all percutaneous revascularization procedures
are associated with transient coronary artery occlusion, and
occlusions are usually done repeatedly during the procedure,
also needs to be considered. Such severe ischemic stress
followed by reperfusion could result in washout of any CK
induced and leaked as a result of the procedure-related
ischemic stress. Some investigators have suggested this from
animal models of repeated coronary occlusion without histo-
logic evidence of myocellular necrosis (97).
Prognostic Relation
There are several possible explanations for the relation
between enzyme appearance and subsequent adverse out-
comes. These include a true effect of myocardial damage,
confoundment with more severe underlying disease and the
play of chance.
Enzymatic rises may occur predominantly in patients with
more severe disease, particularly in those with more diffuse
atherosclerosis; from this perspective, it may not be the
myocardial necrosis reflected by the enzymes themselves that is
creating the risk, but the underlying severity of illness of the
patients. Preliminary analyses have been unable to demon-
strate that the prognostic import of elevated enzymes is
explained by greater underlying disease (75,78). However,
Figure 2. Event-free survival curves for cardiac mortality are shown
for the patient subgroups with high (.3.0 times normal), intermediate
(1.5 to 3.0 times normal) and low (.1.0 to ,1.5 times normal) CK
elevations and for the control group. Freedom from cardiac mortality
after elective PTCA was significantly lower for patients with high and
intermediate CK elevations compared with patients with low CK
elevations and control subjects (p 5 0.007). Reprinted, with permis-
sion, from Kong et al. (84).
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these analyses did not include detailed evaluations of coronary
morphologic characteristics.
A second possibility is that elevated enzymes identify a
particular plaque characteristic that could not be identified
through other means. Such a plaque might be prone to embolic
events at the time of the percutaneous procedure and might be
associated with a poor outcome for reasons independent of the
enzyme elevations. Given that multiple studies have observed
the same relation between enzyme elevation and risk of
adverse outcomes, play of chance cannot be used as an
explanation.
Recommended Interpretation
More high quality data from consecutive patients with
detailed measures of baseline characteristics, procedural de-
tails, periprocedural enzymes and clinical outcomes are
needed. There is a particular need for longer follow-up of
patients, because the life expectancy of many of the patients
exceeds 15 years. A series of critical research questions are in
need of careful clinical investigation (Table 3).
In the interim, however, a CK-MB elevation more than
threefold the upper limit of normal for the reference labora-
tory should be considered an MI. Elevations below threefold
are considered uncertain in terms of their prognostic implica-
tions, although currently available data point to a gradient of
risk with a modest increase in risk of death for slight elevations.
The increase in risk of subsequent cardiac events is clear,
however. In the presence of elevated enzymes before the
procedures, the interpretation is much more complex.
Recommendations for routine clinical care
1. In the clinical care of patients, a preprocedural and post-
procedural ECG should be obtained and the routine mea-
surement of CK and CK-MB is recommended. Ideally,
these measurements should be obtained at baseline and 8
and 16 h after the procedures.
2. Patients with elevations of threefold or more above the
upper limit of normal for percutaneous intervention or
fivefold or more for CABG should be treated as having an
MI, especially in the presence of a technical complication of
the procedures.
3. Elevations less than three- to fivefold are more uncertain,
although any evidence of clinical instability should prompt
caution in discharge and activity instructions.
4. Clinical trials involving coronary revascularization should
obtain ECGs and measure enzymes as described earlier and
at the time of any suspicious clinical event. An independent
and blinded Clinical Events Committee is recommended to
ensure objective evaluation of the end point.
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